X4 PHARMACEUTICALS, INC Debt Securities, Available-for-sale, Amortized Cost
X4 PHARMACEUTICALS, INC (XFOR) had Debt Securities, Available-for-sale, Amortized Cost of $12.88 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $12.88M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $16.82M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $35.94M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $52.56M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $12.88M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $16.82M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $35.94M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $52.56M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $23.75M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $46.70M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $46.36M 10-K · filed 2026-03-17 |
| 2024-09-30 | $37.56M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $21.58M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $20.41M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $14.99M 10-K · filed 2025-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |